GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » Tax Expense

Immunogen (Immunogen) Tax Expense : $0.9 Mil (TTM As of Sep. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Immunogen Tax Expense?

Immunogen's tax expense for the months ended in Sep. 2023 was $-1.2 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.9 Mil.


Immunogen Tax Expense Historical Data

The historical data trend for Immunogen's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Tax Expense Chart

Immunogen Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.22

Immunogen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.22 - 0.88 -1.17

Immunogen Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunogen  (NAS:IMGN) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Immunogen Tax Expense Related Terms

Thank you for viewing the detailed overview of Immunogen's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunogen (Immunogen) Business Description

Traded in Other Exchanges
Address
830 Winter Street, Waltham, MA, USA, 02451
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.
Executives
Theresa Wingrove officer: VP of Regulatory Affairs IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini officer: V.P.-Fin., Prin. Acctg. Off. 830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen officer: Chief Business Officer 11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White officer: SVP, CFO and PFO C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy director, officer: Chief Executive Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos officer: SVP & CHIEF COMMERCIAL OFFICER C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles officer: EVP R&D & MEDICAL AFFAIRS C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char officer: SVP & CHIEF LEGAL OFFICER C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith officer: SVP & Chief Commercial Officer C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain director C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster officer: V.P.-Fin., Prin. Acctg. Off. C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller officer: SVP and CFO 45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows officer: Vice-President,General Counsel C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451